UPDATE : Monday, September 16, 2019
상단여백
Until when will Kolon keep lying about Invossa?
Kolon Life Science’s “explanations” about the mislabeling of the cell ingre...
by Jeong Sae-im  |  2019-05-31 14:59
라인
Samsung BioLogics agrees to manufacture CytoDyn’s HIV drug
Samsung BioLogics said it has signed a deal with U.S. biotech firm CytoDyn ...
by Jeong Sae-im  |  2019-05-31 14:59
라인
Announcement of Invossa license revocation was ‘procedural breach’: Kolon
The government’s recent announcement that it would nullify the license of I...
by Jeong Sae-im  |  2019-05-30 13:28
라인
‘MDM2 gene’ may be associated with hyperprogression after immunotherapy
Oncology researchers around the world are paying keen attention to MDM2 (mo...
by Kim Yun-mi  |  2019-05-29 12:35
라인
Invossa poses almost no safety threat: regulator
The Ministry of Food and Drug Safety said there was no significant concern ...
by Lee Hye-seon  |  2019-05-28 16:02
라인
Brazil OKs Samsung Bioepis’ trastuzumab biosimilar
Brazil’s Agencia Nacional de Vigilancia Sanitaria has granted marketing aut...
by Lee Han-soo  |  2019-05-27 15:52
라인
‘Shareholders can surely win lawsuit against Kolon’
Law firm Hankyul is pursuing a lawsuit against Kolon Life Science and Kolon...
by Jeong Sae-im  |  2019-05-24 19:34
라인
‘Kolon’s extra data insufficient to explain Invossa mislabeling’
The Ministry of Food and Drug Safety said additional material submitted by ...
by Lee Hye-seon  |  2019-05-23 14:51
라인
Prosecutors seek arrest warrant of Samsung BioLogics CEO
The Seoul Central District Prosecutors Office is seeking an arrest warrant ...
by Lee Han-soo  |  2019-05-23 11:19
라인
[News Focus] Kolon, regulator rapped for not doing enough to quell concerns of patients
More than 50 days have passed since the Ministry of Food and Drug Safety (M...
by Jeong Sae-im  |  2019-05-22 11:59
라인
Legislator, activists call for revoking Invossa license, conducting probes
A lawmaker and civic groups urged the government to nullify the license of ...
by Jeong Sae-im  |  2019-05-21 16:03
라인
Kolon to follow 3,700 Invossa-treated patients for 15 years
Kolon Life Science said it would conduct a long-term follow-up study on ove...
by Jeong Sae-im  |  2019-05-17 15:38
라인
Will Celltrion CEO’s bet on ‘bio valley’ pay off?
“It’s been 19 years since I started this business. The first decade was a t...
by Jeong Sae-im  |  2019-05-17 13:21
라인
CHA Biotech’s operating income plunges 92% in Q1
CHA Biotech said in a public filing on Wednesday that it recorded 124.4 bil...
by Jeong Sae-im  |  2019-05-16 13:41
라인
KangStem Biotech completes stem cell drug plant
“KangStem Biotech aims to become a leader in the global stem cell therapy m...
by Jeong Sae-im  |  2019-05-16 11:27
라인
Samsung BioLogics in tight spot amid probe, shareholders’ lawsuit
Prosecutors are speeding up the probe into Samsung BioLogics for alleged ac...
by Jeong Sae-im  |  2019-05-14 14:10
라인
Celltrion’s operating income down 33% in Q1
Biopharmaceutical firm Celltrion said it suffered a 32.9 percent decline in...
by Jeong Sae-im  |  2019-05-09 15:26
라인
If Invossa license gets revoked, Kolon should return $13 million to Mundipharma
The licensing deal between Kolon Life Science and Mundipharma for osteoarth...
by Jeong Sae-im  |  2019-05-08 15:33
라인
Inspection will clear all suspicions over Invossa: TissueGene
Kolon TissueGene finally broke silence amid a growing suspicion that it mig...
by Jeong Sae-im  |  2019-05-08 14:32
라인
Kolon might have covered up Invossa mislabeling for 2 years
Kolon TissueGene said in a public filing that it notified its parent compan...
by Jeong Sae-im  |  2019-05-07 15:55
여백
여백
여백
Back to Top